32 results
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
17 May 24
Results of Operations and Financial Condition
8:27am
negative escape Supported by Phase 1 data in pediatric B-ALL Dual CD19 & BCMA Targeting Designed to induce deep and durable responses Initial Phase 1
10-K
2023 FY
AUTL
Autolus Therapeutics plc
21 Mar 24
Annual report
4:55pm
persistence. Importantly, there were no cases of relapse due to antigen-negative escape, with a median follow-up of 8.7 months. Overall survival was 75% at 6 … on cancer cells. Studies have shown that tumors develop escape mechanisms that prevent T cell-mediated destruction through immune checkpoint proteins
8-K/A
EX-99.1
AUTL
Autolus Therapeutics plc
15 Mar 24
Results of Operations and Financial Condition
4:21pm
a loss of CD19 antigen as of right of escape. And that's certainly shown in ALL. It's clearly shown in obe-cel. So there's a very clear kind of directions
8-K
EX-99.2
AUTL
Autolus Therapeutics plc
14 Mar 24
Results of Operations and Financial Condition
12:32pm
package Dual CD19 & CD22 Targeting Designed to prevent antigen negative escape Supported by Phase 1 data in pediatric B-ALL Dual CD19 & BCMA Targeting
8-K
EX-99.1
AUTL
Autolus Therapeutics plc
13 Feb 24
Regulation FD Disclosure
4:06pm
to prevent antigen negative escape Supported by Phase 1 data in pediatric B-ALL Dual CD19 & BCMA Targeting Designed to induce deep and durable … of leukemic relapse or emergence of MRD related to antigen escape Ghorashian et al., EBMT Annual Meeting 2023 CARPALL Disease Response (n=12) ALLCAR19 Adult ALL
8-K
EX-99.2
jbyxf eege
11 Dec 23
Regulation FD Disclosure
8:31am
10-Q
EX-10.1
dxcgf2tjiqod 7aalkv
9 Nov 23
Quarterly report
4:18pm
424B5
c8qmqjv2o r0
9 Dec 22
Prospectus supplement for primary offering
5:40pm
424B5
6goabduwuwue5icvdoyh
8 Dec 22
Prospectus supplement for primary offering
4:10pm
424B5
oxpng
19 Aug 21
Prospectus supplement for primary offering
4:13pm
F-3
zcugsr5m hq
6 Aug 21
Shelf registration (foreign)
2:30pm
6-K
EX-1
wxdv ayr7wrajqr35p1
30 Jun 21
Annual Report and Accounts
6:05am
424B5
jc0igt
11 Feb 21
Prospectus supplement for primary offering
5:16pm
424B5
z94vn5v0mlr82gk4der1
8 Feb 21
Prospectus supplement for primary offering
5:27pm
424B5
h27 kckciqlyc
18 Sep 20
Prospectus supplement for primary offering
8:01am
6-K
EX-1
ka9ved7zzynwpvv
26 May 20
Current report (foreign)
4:31pm
424B5
m3geeg2mgjfoc7s
24 Jan 20
Prospectus supplement for primary offering
4:11pm